Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters

Database
Country/Region as subject
Language
Affiliation country
Publication year range
1.
J Intellect Disabil Res ; 62(2): 140-149, 2018 02.
Article in English | MEDLINE | ID: mdl-29349928

ABSTRACT

BACKGROUND: Problem behaviours (PBs) are a common cause for clinician contact in people with disorders of intellectual development and may be a common cause for the prescription of psychotropic medication. We aimed to use a large, multinational sample to define the prevalence of PBs, the associations with psychotropic medication use, and to assess for any potential 'diagnostic overshadowing' by the label of PBs in a population of people with disorders of intellectual development. METHOD: A multinational, multi-setting, cross-sectional service evaluation and baseline audit was completed. Data were collected from UK hospitals, UK community settings, Sri Lanka and Hong Kong. A semi-structured questionnaire was completed by treating clinicians, capturing demographic details, prevalence rates of intellectual disability and psychotropic medication use, alongside psychiatric co-morbidity. RESULTS: A sample size of 358 was obtained, with 65% of included participants treated in an inpatient setting. Psychotropic use was prevalent (90%) in our sample, particularly antipsychotics (74%). The prevalence of PB was high (83%). There was no statistically significant association between psychotropic prescription and recorded psychiatric co-morbidity, suggesting prevalent 'off-label' use for PBs, or poor recording of psychiatric co-morbidity. There was some evidence of possible diagnostic overshadowing due to the PB classification. A higher dose of psychotropic medication was associated with aggression toward others (P = 0.03). CONCLUSIONS: We found evidence of prevalent potential 'off-label' use for psychotropic medication, which may be due to PBs. We also found evidence of potential diagnostic-overshadowing, where symptoms of psychiatric co-morbidity may have been attributed to PBs. Our findings provide renewed importance, across borders and health systems, for clinicians to consider a holistic approach to treating PBs, and attempting to best understand the precipitants and predisposing factors before psychotropic prescribing.


Subject(s)
Behavioral Symptoms , Intellectual Disability , Off-Label Use , Psychotropic Drugs/therapeutic use , Adult , Antipsychotic Agents/therapeutic use , Behavioral Symptoms/diagnosis , Behavioral Symptoms/drug therapy , Behavioral Symptoms/epidemiology , Behavioral Symptoms/etiology , Comorbidity , Cross-Sectional Studies , Female , Hong Kong/epidemiology , Humans , Intellectual Disability/complications , Intellectual Disability/drug therapy , Intellectual Disability/epidemiology , Male , Middle Aged , Off-Label Use/statistics & numerical data , Prevalence , Problem Behavior , Sri Lanka/epidemiology , United Kingdom/epidemiology
SELECTION OF CITATIONS
SEARCH DETAIL